

Package leaflet: Information for the user
INTERIM AUTHORISATION
Spikevax
0.1 mg/mL dispersion for injection
COVID-19 mRNA Vaccine (nucleoside modified)
elasomeran

The HSA has granted interim authorisation of Spikevax to prevent COVID-19 in individuals 6 months of age and older under the Pandemic Special Access Route (PSAR).

For more information on Interim Authorisation under PSAR, visit HSA at <https://www.hsa.gov.sg/therapeutic-products/register/special-access-routes/psar-emergency-therapeutic-product>.

Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Spikevax is and what it is used for
2. What you need to know before you are given Spikevax
3. How Spikevax is given
4. Possible side effects
5. How to store Spikevax
6. Contents of the pack and other information

1. What Spikevax is and what it is used for

Spikevax is a vaccine used to prevent COVID-19 disease caused by SARS-CoV-2. It is given to individuals aged 6 months and older. The active substance in Spikevax is mRNA encoding the SARS-CoV-2 Spike protein. The mRNA is embedded in SM-102 lipid nanoparticles.

As Spikevax does not contain the virus, it cannot give you COVID-19.

How the vaccine works

Spikevax stimulates the body's natural defences (immune system). The vaccine works by causing the body to produce protection (antibodies) against the virus that causes COVID-19. Spikevax uses a substance called messenger ribonucleic acid (mRNA) to carry instructions that cells in the body can use to make the spike protein that is also on the virus. The cells then make antibodies against the spike protein to help fight off the virus. This will help to protect you against COVID-19.

2. What you need to know before you are given Spikevax

The vaccine must not be given if

- you are **allergic** to the active substance or any of the other ingredients of this vaccine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given Spikevax if:

- you have previously had a severe, life-threatening **allergic** reaction after any other vaccine injection or after you were given Spikevax in the past.
- you have any allergies
- you have a very weak or compromised immune system

- you have ever fainted following any needle injection.
- you have a bleeding disorder
- you have a fever
- you are pregnant or plan to be pregnant
- you are breastfeeding
- you have any serious illness
- you have received another COVID-19 vaccine
- if you have anxiety related to injections

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) after vaccination with Spikevax (see section 4).

These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males.

The chance of having this occur is very low. You should avoid strenuous physical activity for two weeks after vaccination. You should seek medical attention right away if you have any of the following symptoms after receiving Spikevax:

- Chest pain
- Shortness of breath
- Feelings of having a fast-beating, fluttering, or pounding heart

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Spikevax.

As with any vaccine, the primary 2-dose vaccination course of Spikevax may not fully protect all those who receive it and it is not known how long you will be protected.

Children

Spikevax is not recommended for children aged under 6 months old.

Other medicines and Spikevax

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Spikevax may affect the way other medicines work, and other medicines may affect how Spikevax works.

Immunocompromised individuals

If you are immunocompromised, you may receive a third dose of Spikevax. The efficacy of Spikevax even after a third dose may be lower in people who are immunocompromised. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. In addition, your close contacts should be vaccinated as appropriate. Discuss appropriate individual recommendations with your doctor.

Driving and using machines

Do not drive or use machines if you are feeling unwell after vaccination. Wait until any effects of the vaccine have worn off before you drive or use machines.

Spikevax contains sodium

Spikevax contains less than 1 mmol (23 mg) sodium per dose and, that is to say, essentially 'sodium-free'.

3. How you will be given Spikevax

Vaccination	0.10 mg/mL concentration
Primary series It is recommended to get the second dose of the same vaccine 28 days after the first dose to complete the vaccination course.	<i>Children 6 months through 5 years of age</i> two 0.25 mL injections
Booster dose	<i>Individuals 18 years of age and older</i> 0.5 mL

If you are immunocompromised, you may receive a third dose of Spikevax.

If you miss an appointment for your primary 2nd dose of Spikevax

- If you miss an appointment, arrange another visit as soon as possible with your doctor, nurse, or pharmacist.
- If you miss a scheduled injection, you may not be fully protected against COVID-19.

Your doctor, pharmacist or nurse will inject the vaccine into a muscle (intramuscular injection) in your upper arm.

During and after each injection of the vaccine, your doctor, pharmacist or nurse will watch over you for around 30 minutes to monitor for signs of an allergic reaction.

If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this vaccine can cause side effects, although not everybody gets them.

Get **urgent** medical attention if you get any of the following signs and symptoms of an allergic reaction:

- feeling faint or light-headed;
- changes in your heartbeat;
- shortness of breath;
- wheezing;
- swelling of your lips, face, or throat;
- hives or rash;
- nausea or vomiting;
- stomach pain.

Talk to your doctor or nurse if you develop any other side effects. These can include:

Very common (may affect more than 1 in 10 people):

- swelling in the underarm
- decreased appetite (observed in 6 month to 5 year olds)
- irritability/crying (observed in 6 month to 5 year olds)
- headache
- sleepiness (observed in 6 month to 5 year olds)
- nausea
- vomiting
- muscle ache, joint aches, and stiffness
- pain or swelling at the injection site

- redness at the injection site (some of which may occur approximately 9 to 11 days after the injection)
- feeling very tired
- chills
- fever

Common (may affect up to 1 in 10 people):

- rash
- rash or hives at the injection site (some of which may occur approximately 9 to 11 days after the injection)

Uncommon (may affect up to 1 in 100 people):

- itchiness at the injection site
- dizziness
- stomach pain

Rare (may affect up to 1 in 1,000 people)

- temporary one-sided facial drooping (Bell's palsy)
- swelling of the face (Swelling of the face may occur in patients who have had facial cosmetic injections.)
- decreased sense of touch or sensation
- unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)
- raised, itchy rash (urticaria) (some of which may occur approximately 7 to 13 days after the injection)

Very rare (may affect up to 1 in 10,000 people)

- inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis) which can result in breathlessness, palpitations or chest pain

Frequency unknown

- severe allergic reactions (anaphylaxis)
- hypersensitivity

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

5. How to store Spikevax

Keep this vaccine out of the sight and reach of children.

Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Information about storage, expiry, and use and handling are described in the section intended for healthcare professionals at the end of the package leaflet.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Spikevax contains

Concentration	Presentation	Dose(s)	Composition
0.10 mg/mL			

	Multidose vial	5 doses of 0.5 mL each	One dose (0.5 mL) contains 50 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in SM-102 lipid nanoparticles).
		10 doses of 0.25 mL each	One dose (0.25 mL) contains 25 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles).
	Pre-filled syringe	1 dose of 0.5 mL Do not use the pre-filled syringe to deliver a partial 0.25 mL volume.	One dose (0.5 mL) contains 50 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embedded in SM-102 lipid nanoparticles).

Single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2.

The other ingredients are SM-102, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine(DSPC), 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000 DMG), trometamol, trometamol hydrochloride, acetic acid, sodium acetate trihydrate, sucrose, water for injections.

What Spikevax looks like and contents of the pack

Multidose vial

Spikevax is a white to off white dispersion supplied in a glass vial with a rubber stopper and aluminium seal.

Pack size: 10 multidose vials

Pre-filled syringe

Spikevax is a white to off white dispersion supplied in a pre-filled syringe.

Pack size: 10 pre-filled syringes

Product owner:

MODERNA BIOTECH SPAIN, S.L.
Calle del Príncipe de Vergara 132 Plt 12
Madrid 28002
Spain

Manufacturer:

For multidose vial:

Rovi Pharma Industrial Services, S.A.
Paseo de Europa, 50
28703. San Sebastián de los Reyes
Madrid, Spain

For pre-filled syringe:

Rovi Pharma Industrial Services, S.A.
Calle Julián Camarillo nº35
28037 Madrid Spain

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

This leaflet was last revised in 10/2022.

Scan the code with a mobile device to get the package leaflet in different languages.



Or visit the URL <https://www.ModernaCovid19Global.com>

The following information is intended for healthcare professionals only:

Spikevax 0.1 mg/mL is supplied in the following presentations:

- Multidose vial (blue cap): For administration as a primary series to individuals 6 months through 5 years, and as a booster dose in individuals 18 years and older
- Pre-filled syringe: For administration as a booster dose in individuals 18 years and older

Only the multidose vial (blue cap) may be used for vaccine administration to children 6 months through 5 years.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Storage and preparation for administration

Spikevax should be administered by a trained healthcare professional. The vaccine comes ready to use once thawed.

Do not shake or dilute.

Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.

Spikevax is a white to off-white dispersion. It may contain white or translucent product-related particulates. Do not administer if vaccine is discoloured or contains other particulate matter.

Multidose vials

Spikevax vials are multidose.

Pierce the stopper preferably at a different site each time.

Pre-filled syringe

Spikevax is supplied in a single-dose, pre-filled syringe (without needle) containing 0.5 mL (50 micrograms) mRNA and must be thawed prior to administration.

During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

Storage Condition	Storage Temperature	Storage Duration
-------------------	---------------------	------------------

Frozen	-50°C to -15°C	Until expiry
Refrigerated	2°C to 8°C	Up to 30 days until expiry. Do not refreeze.
Ambient	8°C to 25°C	Up to 24 hours. Do not refreeze.

The vaccine comes ready to use once thawed. Thaw each syringe before use following the instructions below.

Thaw in refrigerator	Thaw at room temperature
Thaw between 2°C to 8°C for 2 hours. Let each syringe stand at room temperature (15°C to 25°C) for 15 minutes before administering.	Alternatively, thaw between 15°C to 25°C for 1 hour.

After thawing, do not refreeze.

Thawed vials and pre-filled syringes can be handled in room light conditions.

Dosing and schedule

Vaccination	0.10 mg/mL concentration
Primary series It is recommended to get the second dose of the same vaccine 28 days after the first dose to complete the vaccination course.	<i>Children 6 months through 5 years of age</i> two 0.25 mL injections
Booster dose	<i>Individuals 18 years of age and older</i> 0.5 mL

A third dose may be given to individuals who are immunocompromised.

As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in the event of an anaphylactic reaction following the administration of Spikevax. Individuals should be observed by a healthcare professional for at least 30 minutes after vaccination.

There are no data to assess the concomitant administration of Spikevax with other vaccines. Spikevax must not be mixed with other vaccines or medicinal products in the same syringe.

Administration

The vaccine must be administered intramuscularly. The preferred site is the deltoid muscle of the upper arm, or in infants and young children, the anterolateral aspect of the thigh. Do not administer this vaccine intravascularly, subcutaneously or intradermally.

Remove tip cap from pre-filled syringe by twisting in a counter-clockwise direction. Use a sterile needle of the appropriate size for intramuscular injection.

Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe. Administer the entire dose intramuscularly. Discard syringe after use.